Opinion
The results of the company’s Phase 2b trial raise concerns around safety, efficacy, and money, suggesting key questions to be addressed in Phase 3.
UNIFY founder Adil Kassam discusses how technology coupled with global group meditation can facilitate synchronized transformational experiences among millions of people.
The medicalization of psychedelics may be changing people’s minds, but can these developments result in deeper changes in how we view or access medicine?
Psychedelic medicines make headlines for indications like PTSD, depression, and anxiety, but they’re being studied for a much broader range of conditions.
Game designer Robin Arnott discusses how psychedelics and virtual reality might collide, the potential risks of “digital psychedelics,” and how to Trojan Horse transformational experiences into virtual worlds.
Between tripping hard on 200 mcgs of acid and microdosing lies a vast dosing territory ripe for exploration and flow states.
After being diagnosed with cancer two days before his wedding, Steven Allgood turned to psilocybin to alleviate his end-of-life anxiety, and transform his perspective on life and what may come after.
The way patents in the psychedelic field can pose a problem is often misunderstood, mischaracterized, and sensationalized by the media and academics alike.
If all goes well, in two years MDMA will become the first Schedule 1 psychedelic to cross the federal approval finish line and become a prescription medication.
Nick Janicki of True REST float spas discusses combining psychedelics with float tanks, the problem with transhumanism, and expanding consciousness through float tanks, plunges and saunas.
